More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Fintel reports that on December 23, 2024, Jefferies downgraded their outlook for Mesoblast Limited - Depositary Receipt () ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...

After years of trying, Mesoblast has won US FDA approval for its stem-cell therapies to treat the fatal graft-versus-host ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

The Mesoblast Ltd (ASX: MSB) share price is taking a dive today. Here’s why the biotech stock is under pressure after ...

Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

Mesoblast snagged FDA approval late Wednesday for the first-ever treatment for children with a form of GVHD. The biotech ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Mesoblast ( (MESO) ) has shared an update.

Mesoblast (NASDAQ:MESO – Get Free Report) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat ...